Physician profile
Ravinderjit Singh
NPI 1265695563
$4,617.07
in general payments reported to CMS, 2019-2025
13 companies · $749 in 2025
The $749 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $310 · 2021: $502 · 2022: $1,105 · 2023: $373 · 2024: $595 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.64 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $694.06 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $633.09 | 2019-2025 | Abilify Asimtufii |
| Alkermes, INC. | $591.09 | 2019-2024 | Lybalvi, Aristada |
| Abbvie INC. | $539.36 | 2022-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $498.59 | 2022-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $401.50 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $310.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.30 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $216.73 | 2024-2025 | Auvelity |
| Allergan, INC. | $215.21 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $140.99 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.19 | 2019 | |
| Lundbeck LLC | $24.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinderjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.